Get the Stockscreener App
3.58
2.87%
+0.10
After Hours:
3.55
-0.03
-0.84%
ARCA biopharma Inc stock is currently priced at $3.58, with a 24-hour trading volume of 85,291.
It has seen a +2.87% increased in the last 24 hours and a +109.36% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $3.52 pivot point. If it approaches the $3.62 resistance level, significant changes may occur.
Previous Close:
$3.48
Open:
$3.68
24h Volume:
85,291
Market Cap:
$51.91M
Revenue:
-
Net Income/Loss:
$-5.34M
P/E Ratio:
-8.3256
EPS:
-0.43
Net Cash Flow:
$-5.01M
1W Performance:
+5.29%
1M Performance:
+109.36%
6M Performance:
+82.65%
1Y Performance:
+79.00%
1D Range:
$3.5001
$3.68
52W Range:
$1.56
$3.88
ARCA biopharma Inc Stock (ABIO) Company Profile
Name
ARCA biopharma Inc
Sector
Industry
Phone
720 940 2200
Address
10170 Church Ranch Way, Suite 100, Westminster, CO
ARCA biopharma Inc Stock (ABIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-27-18 | Initiated | Ascendiant Capital Markets | Buy |
| Oct-09-13 | Initiated | Dawson James | Buy |
ARCA biopharma Inc Stock (ABIO) Latest News
ARCA biopharma Announces First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire Inc.
Why STAAR Surgical Shares Are Trading Higher By Around 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Benzinga
Why Flora Growth Shares Are Trading Lower By Around 20%; Here Are 20 Stocks Moving Premarket
Benzinga
Nasdaq Gains 75 Points; Acuity Brands Posts Upbeat Earnings
Benzinga
Why Ulta Beauty Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Benzinga
Crude Oil Moves Higher; ISM Services PMI Falls In March
Benzinga
ARCA biopharma Inc Stock (ABIO) Financials Data
ARCA biopharma Inc (ABIO) Net Income 2024
ABIO net income (TTM) was -$5.34 million for the quarter ending December 31, 2023, a +46.21% increase year-over-year.
ARCA biopharma Inc (ABIO) Cash Flow 2024
ABIO recorded a free cash flow (TTM) of -$5.01 million for the quarter ending December 31, 2023, a +54.06% increase year-over-year.
ARCA biopharma Inc (ABIO) Earnings per Share 2024
ABIO earnings per share (TTM) was -$0.37 for the quarter ending December 31, 2023, a +46.38% growth year-over-year.
About ARCA biopharma Inc
ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure. ARCA biopharma, Inc. has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial; and research collaboration with Colorado Prevention Center, the University of Colorado's Academic Research Organization to develop and commercialize Gencaro. The company was incorporated in 2004 and is headquartered in Westminster, Colorado.
1.53%
3.38%
Cap:
|
Volume (24h):